
Larimar Therapeutics, Inc.: updates and filings
Price
$3.14
November 20, 2026Market cap $326M
What Ploutos Investor adds for Larimar Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 16, 2026next Feb 12, 2027
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Shares registered for employeesFormS-8
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Results of operationsForm8-K
- Nov 9, 2026Results of operations, other material eventsForm8-K
- Sep 29, 2026Officer or director changeForm8-K
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operations, other material eventsForm8-K
- Jun 29, 2026Other material eventsForm8-K
- May 19, 2026Shareholder voteForm8-K
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operations, other material eventsForm8-K
- Apr 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 20, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 20, 2026Annual meeting proxy statementFormDEF 14A
- Apr 10, 2026Preliminary proxy statementFormPRE 14A
- Mar 19, 2026Shares registered for employeesFormS-8
- Mar 19, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 19, 2026Results of operationsForm8-K
- Mar 9, 2026Other material eventsForm8-K
- Mar 2, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 27, 2026Material agreement enteredForm8-K
- Feb 24, 2026Other material eventsForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | S-8 | Shares registered for employees | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Nov 9, 2026 | 8-K | Results of operations, other material events | Document |
| Sep 29, 2026 | 8-K | Officer or director change | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations, other material events | Document |
| Jun 29, 2026 | 8-K | Other material events | Document |
| May 19, 2026 | 8-K | Shareholder vote | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations, other material events | Document |
| Apr 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 20, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 20, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 10, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Mar 19, 2026 | S-8 | Shares registered for employees | Document |
| Mar 19, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 19, 2026 | 8-K | Results of operations | Document |
| Mar 9, 2026 | 8-K | Other material events | Document |
| Mar 2, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 27, 2026 | 8-K | Material agreement entered | Document |
| Feb 24, 2026 | 8-K | Other material events | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 28, 2006.
The full analysis
What do Larimar Therapeutics's filings show?
The filings are where every one of Larimar Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.